The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood‐borne metastasis via an invasion‐independent pathway
- 11 May 2007
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 212 (2) , 152-160
- https://doi.org/10.1002/path.2156
Abstract
An invasion‐independent pathway has been proposed as a novel mechanism in blood‐borne metastasis, where tumour cells enveloped by sinusoidal tumour vessels enter the circulation without vascular invasion. We previously identified the secretory leukocyte protease inhibitor (SLPI) as a candidate gene responsible for this pathway. In this study, the functional role of SLPI in metastatic dissemination was investigated. We transfected the SLPI gene into a poorly metastatic clone of the MCH66 mouse mammary tumour cell line. Over‐expression of SLPI promoted in vivo growth and spontaneous metastasis to the lung, whereas it suppressed invasive activity in vitro. The inoculated tumours of SLPI‐transfectants exclusively induced a sinusoidal vasculature and subsequently produced endothelial‐coated tumour emboli, which are morphological indices of the invasion‐independent pathway. In addition, exogenous SLPI inhibited the migration activity through Matrigel of both tumour cells and human umbilical vein endothelial cells (HUVECs). In vivo angiogenesis assays also demonstrated that SLPI suppressed the migration of newly formed blood vessels. These results suggest that an anti‐migratory effect of SLPI on tumour‐associated endothelial cells may induce vascular remodelling to form a sinusoidal architecture, and consequently promote invasion‐independent metastasis. This study provides a new model for metastasis, based on the mechanism regulated by anti‐invasive factors, such as SLPI. Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 21 references indexed in Scilit:
- Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive DiseaseCancer Research, 2005
- Role of imbalance between neutrophil elastase and α1-antitrypsin in cancer development and progressionThe Lancet Oncology, 2004
- Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cellsProceedings of the National Academy of Sciences, 2003
- Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases.Journal of Clinical Investigation, 1997
- Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.Journal of Clinical Investigation, 1995
- Sequential process of blood‐borne lung metastases of spontaneous mammary carcinoma in C3H miceInternational Journal of Cancer, 1993
- A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.1992
- Tissue distribution of antileukoprotease and lysozyme in humans.Journal of Histochemistry & Cytochemistry, 1989
- The biology of cancer metastasis and implications for therapyCurrent Problems in Surgery, 1987
- Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase.Proceedings of the National Academy of Sciences, 1986